Clinuvel Pharmaceuticals Limited [ASX:CUV] share price and news 2022

Company Description

Clinuvel Pharmaceuticals Limited (CUV) is a global biopharmaceutical company focused on developing delivering treatments for patients with a range of genetic and vascular disorders. CUV’s lead compound is SCENESSE (afamelanotide), a drug targeting erythropoietic protoporphyria (EPP).

Clinuvel Pharmaceuticals Limited belongs to Health Care sector and under industry of Biotechnology. You can get more information about this company via their website:

This a small cap company with market cap of 1250 millions.

Compared to Market and Sector

The following table compares the company to Market and Sector based on Earning, Price/Earning ratio(P/E), Price/Book ratio (P/B) and PE growth.

Company PE is greater than both sector and market. while Company PB is greater than both sector and market. On the other hand,

Earnings PE PB PE growth
Company 0.91 76.7 17 0
Market 0.85 22.3 1.99 0.84
Sector 1.7 39.6 5.78 0.26

Dividend Growth Chart

The following chart shows you how cuv dividend grows in the recent years.Clinuvel Pharmaceuticals Limited has dividend yield of 0.10%